Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul;15(6):448–445. doi: 10.2174/1570162X16666171206121026

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Bentham Science Publishers

This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

PMC Copyright notice

Fig. (2) — Median levels of total HIV-DNA in 161 patients on stable ART stratified on the basis of therapy protocols. 358, 234, 343 and 260 represent the median copy numbers of HIV DNA load detected in HIV patients undergoing different therapy protocols. From left to right: patients receiving abacavir/lamivudine (ABC/3TC) or emtricitabine/tenofovir diproxil (FTC/TDF) plus one non-nucleoside reverse trascriptase inhibitor (NNRTI, efavirenz or etravirine or rilpivirine) (group I) or nevirapine (group II); patients receiving abacavir/lamivudine (ABC/3TC) or emtricitabine/tenofovir diproxil (FTC/TDF) plus one boosted protease inhibitor (PI/r, darunavir/ritonavir) (group III), and patients receiving an integrase inhibitor (INI) such Raltegravir (RAL) plus darunavir/ritonavir (group IV).